Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival

BACKGROUND: Matrix metalloproteinase-9 (MMP9) selectively cleaves extracellular matrix proteins contributing to tumor growth and an immunosuppressive microenvironment. This study evaluated andecaliximab (ADX), an inhibitor of MMP9, in combination with nivolumab (NIVO), for the treatment of advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Manish A, Cunningham, David, Metges, Jean-Philippe, Van Cutsem, Eric, Wainberg, Zev, Elboudwarej, Emon, Lin, Kai-Wen, Turner, Scott, Zavodovskaya, Marianna, Inzunza, David, Liu, Jinfeng, Patterson, Scott D, Zhou, Jingzhu, He, Jing, Thai, Dung, Bhargava, Pankaj, Brachmann, Carrie Baker, Cantenacci, Daniel V T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666898/
https://www.ncbi.nlm.nih.gov/pubmed/34893523
http://dx.doi.org/10.1136/jitc-2021-003580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666898/
https://www.ncbi.nlm.nih.gov/pubmed/34893523
http://dx.doi.org/10.1136/jitc-2021-003580

Ejemplares similares